Moreover, studies based on a nanobody-based anti-proteome approach revealed that TRIM28 can be employed as a diagnostic marker for distinguishing glioblastomas from lower-grade gliomas [102]. The gene discussed is TRIM28; the disease is central nervous system cancer.